The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 PseudovirusSARS-CoV-2 계통 B.1.351 슈도바이러스의 감염성 및 중화 효율에 미치는 영향Communication Published on 2021-04-072022-09-01 Journal: Viruses [Category] MERS, SARS, 변종, 진단, [키워드] affected antibody B.1.351 Casirivimab D614G E484K E484K mutation E484K mutations Efficacy Efficiency Imdevimab Impact indicated Infectivity investigated K417N K417N and E484K mutation of spike Lineage monoclonal antibodies multiple mutation multiple mutations mutant Mutation N501Y N501Y mutation neutralization neutralized Neutralizing antibodies pseudovirus pseudoviruses raising RBD Receptor-binding domain referred to SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 variant significantly increased South Africa Strains tested the receptor-binding domain Transmissibility variant of SARS-CoV-2 Viral viral infectivity viral spread Wuhan Wuhan strain [DOI] 10.3390/v13040633 PMC 바로가기 [Article Type] Communication
Neutralizing Antibody Therapeutics for COVID-19COVID-19에 대한 중화 항체 치료제Review Published on 2021-04-072022-09-01 Journal: Viruses [Category] SARS, 변종, 진단, 치료제, [키워드] administration ambulatory patient ambulatory patients Antiviral Antiviral treatment authorization bamlanivimab Casirivimab Clinical management COVID-19 COVID-19 pandemic COVID-19 patient drug Drug administration effective Emergency Emergency use authorization etesevimab European Medicines Agency food global public health high risk highlighting Hospitalized hospitalized patient hospitalized patients Imdevimab IMPROVE monotherapy mutant NAb NAbs neutralizing antibody Occurrence oxygen Patient progressed Prophylactic Prophylaxis Randomized controlled trial resistance risk SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody severe COVID-19 severe disease subsequent supplemental oxygen susceptibility Therapeutic strategies Therapeutics Treatment US Food and Drug Administration variant with COVID-19 [DOI] 10.3390/v13040628 PMC 바로가기 [Article Type] Review
A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities이동식 장치는 전문 의료 시설에서 COVID-19에 대한 단일 클론 항체 주입에 대한 문제를 극복합니다Article Published on 2021-04-012022-09-12 Journal: Journal of the American Geriatrics Society [Category] 진단, [키워드] administer adverse event age anti-spike monoclonal antibody authorization average bamlanivimab Care Casirivimab cohort study collaboration Coronavirus disease-19 COVID-19 COVID-19 complications COVID-19 diagnosis COVID-19 patient deaths Efficacy Emergency event rate FDA FIVE frailty high risk hospitalizations implementation increased risk infused infusion Mayo Clinic monoclonal antibodies monoclonal antibody occurred offered outcomes overcome Patient patients with COVID-19 registered nurse reported resident SARS-CoV-2 supported Therapies therapy Treatment [DOI] 10.1111/jgs.17090 PMC 바로가기 [Article Type] Article
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemicCOVID-19 전염병 동안 접근 프로그램 확대, 동정적 약물 사용 및 긴급 사용 승인Review Published on 2021-02-012022-09-11 Journal: Drug discovery today [Category] MERS, SARS, 신약개발, 진단, 치료제, [키워드] access approval approved authorization bamlanivimab Baricitinib Casirivimab clinical trials compassionate use convalescent plasma coronavirus COVID-19 COVID-19 pandemic description diagnostics drug Effectiveness Emergency EUA Expanded access Experimental drugs FDA focus food Hydroxychloroquine Imdevimab Infectious disease pandemic pharmacological Program propofol Remdesivir ruxolitinib Threats US Food and Drug Administration Vaccine while [DOI] 10.1016/j.drudis.2020.11.025 PMC 바로가기 [Article Type] Review
Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and AdolescentsArticle Published on 2021-01-032023-07-02 Journal: Journal of the Pediatric Infectious Diseases Socie [Category] SARS, [키워드] bamlanivimab Casirivimab COVID-19 Imdevimab pediatric [DOI] 10.1093/jpids/piaa175 PMC 바로가기
Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19경증-중등도 COVID-19 고위험군 환자의 단클론항체 치료 동의 결정에 대한 사회적, 문화적 요인의 영향Article Published on 2021-01-012022-09-12 Journal: Journal of primary care & community health [Category] MERS, 진단, [키워드] age anti-spike monoclonal antibody bamlanivimab Casirivimab chose Clinical outcome Comorbidities confidence Consent coronavirus covid_19 COVID-19 COVID-19 diagnosis Cultural decision declined effort Endpoint English enrolled Factor Gender high risk Hospitalization identify Imdevimab impacted influence interval lack Mayo Clinic monoclonal monoclonal antibodies monoclonal antibody monoclonal antibody treatment offer offered Patient patient outcomes populations primary endpoint public health Rate Ratio reduce retrospective cohort study sars_cov-2. secondary Support Therapies therapy Treatment white [DOI] 10.1177/21501327211019282 PMC 바로가기 [Article Type] Article
Antibodies to watch in 20212021년에 주목해야 할 항체Review Published on 2021-01-012022-08-31 Journal: mAbs [Category] 신약개발, 진단, 치료제, [키워드] added addition amivantamab anti-SARS-CoV antibody antibody Antibody therapeutics approval approvals approved array bamlanivimab Cancer Casirivimab clinical study coronavirus disease Coronavirus disease 2019 COVID-19 disorders drug Drug administration Emergency use European European Medicines Agency event faricimab FDA food Food and Drug Administration Healthcare system Immune-mediated immune-mediated disorders. India indication indications information itolizumab Japan mAbs Medicine occur occurred pandemic Potential treatment potential treatments proof Record Registered Regulatory Russia SARS-CoV-2 sodium submission submitted tanezumab Treatment treatments for COVID-19 US Food and Drug Administration [DOI] 10.1080/19420862.2020.1860476 PMC 바로가기 [Article Type] Review